Omalizumab for pediatric allergic asthma: evidence-based insights on efficacy and safety from a meta-analysis of randomized trials. (PubMed, Front Pharmacol) - Oct 10, 2026 - "These findings support its use as an add-on therapy for moderate-to-severe disease inadequately controlled by standard treatments. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251132811, identifer CRD420251132811."
Journal • Retrospective data • Review • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases
|
|
Bin Chen; Jinbiao Han; Shanshan Wu; Zhuan Zou
|